Rate cut decisions by the US Federal Reserve impact the Indian stock market, as it weighs or boosts several rate sensitive stocks.
The executives of the companies say by pairing weight-loss drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) with diet plans, lab monitoring, and strength training, patients will achieve safer, sustained results.
The Nifty Capital Markets index has now extended losses for the third consecutive session, closing at 4,482.10 on Wednesday
The outcome of Fed's meeting will likely impact investor sentiment around IT stocks as these Indian companies derive a significant portion of their revenue from the US market.
Kaynes Technology share price: The sharp selloff in the stock began after Kotak Institutional Equities raised concerns over inconsistencies in the EMS player's related-party disclosures.
Sun Pharma, like Dr Reddy's Lab, can't sell semaglutide-based products in India until March 2026 when Novo Nordisk’s patent expires
Swiggy share price: The shares of the food delivery and quick commerce giant rose to Rs 406.90 apiece, the highest level seen by the stock in nearly two weeks.
Nephrocare Health Services IPO GMP: The price band for the IPO has been set at Rs 438-460 per share.
Corona Remedies IPO GMP: Corona Remedies IPO is entirely an offer-for-sale of shares at a price band of Rs 1,008-1,062 apiece.
Park Medi World is the second-largest private hospital chain in North India with 3,000 beds, and the largest in Haryana with 1,600 beds.
This article explores the tension between shareholder decisions and the institutional mechanisms that delay or override them, examining cases like Tesla and Vedanta to highlight procedural hurdles in corporate governance
'For investors, now is less about chasing quick rebounds and more about anchoring on balance sheets, capacity utilisation and long-term demand visibility,' an analyst said.
Hindustan Zinc share price: The shares of the Vedanta Group-company rose to Rs 515 apiece in the morning trading hours of Wednesday, the highest level seen by the stock in more than seven weeks.
Groww share price: Approximately 2% of the company's outstanding equity, cumulatively worth around Rs 2,230 crore, have become eligible for trading after the expiry of the lock-in period.
Union Civil Aviation Minister Ram Mohan Naidu said that the government considers it necessary to curtail the overall Indigo routes, which will help in stabilizing the airline’s operations and lead to reduced cancellations.
The fresh plea follows a recent court order allowing Dr. Reddy’s Laboratories (DRL) to continue manufacturing and exporting its version of semaglutide while prohibiting domestic sales until Novo Nordisk’s patent expires.
Park Medi World IPO | The Rs 920-crore initial public offering will open during December 10-12, with price band of Rs 154-162 per share.
The Nephrocare Health Services IPO is a combination of fresh issuance of shares worth Rs 353.4 crore, and an offer-for-sale of 1.12 crore shares by existing shareholders.
KSH International IPO | The stake sale has done at a price of Rs 384 per share, valuing the company at little more than Rs 2,600 crore.
Steamhouse India IPO | The company proposed to mobilise Rs 345 crore by issuing fresh shares, while promoter Vishal Sanwarprasad Budhia will offload shares worth up to Rs 80 crore via offer-for-sale.
The move is significant because Keytruda, one of the world’s top-selling immunotherapies with annual sales exceeding $20 billion, faces a looming patent expiry in 2028 in the US, opening the door for biosimilar competition in a market dominated by high-cost oncology drugs.
Swiggy said it may offer a discount of not more than 5% on the floor price calculated for the issue.
The SEBI had put the issuance of observations on Sterlite Electric’s IPO papers in abeyance on October 27.
Aequs listing expectations: Analysts advised investors to book partial profits on listing gains and holding the rest for long term.
The ‘Why We Work’ study reveals key motivators for Indian professionals, highlighting the importance of risk, resilience, and reward in shaping career paths, offering insights for both employees and organisations
